StockpollyBeta
Get App
Popularity #1,082
ARGX · NASDAQ · Biotechnology

argenx (ADR) (ARGX)

Develops antibody medicines for severe autoimmune diseases around the VYVGART franchise.

$952.11
vs last close−11.68 (−1.21%)

In millions of USD, except per-share figures

In millionsQ1 FY23Mar 2023Q2 FY23Jun 2023Q3 FY23Sep 2023Q4 FY23Sep 2023Q2 FY24Mar 2024Q1 FY24Mar 2024Q3 FY24Sep 2024Q4 FY24Sep 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q4 FY25Dec 2025Q2 FY26Jun 2026
Revenue−2584683303304014015735737919483,2062,816
Cost of revenue−80837036364343595981111340279
Gross profit5501072942943583585145147108372,8662,536
5072873743744514515005005696332,0151,690
Research & development−115331192192225225236236309328443486
−131285192192236236278278276321355773
Selling & marketing2020000000000240
General & administrative5070000000000533
Other expenses752−359−9−9−10−10−14−14−17−161,217431
Operating income43−189−81−81−93−931414141204851847
1446−3−3191974746183141112
Interest income33730303939414137384492
Interest expense000011111112
Other non-operating income−120−222−20−20−75−75−62−84−1440
Income before tax56−147−83−83−74−748888202287992959
Income tax expense10−34−11−11−13−13−3−33342−55119
Net income from continuing operations46−113−73−73−62−6291911692451,047840
Other adjustments00000000000−1
Net income46−113−73−73−62−6291911692451,047839
EPS, basic$0.77−$2.03−$1.25−$1.25−$1.04−$1.04$1.52$1.52$2.78$6.85$14.25$13.49
EPS, diluted$0.77−$2.03−$1.25−$1.25−$1.04−$1.04$1.39$1.39$2.58$6.37$13.22$13.02
Weighted average shares, basic565658585959606061616162
Weighted average shares, diluted565658585959666666666664
EBITDA156−183−83−83−74−7489892032881,009864
Depreciation & amortization164000000001517
EBIT163−187−83−83−74−748989203288995847